Four things to know · April 15, 2026
BPC-157
Body Protection Compound-157
BPC-157 is a peptide studied for its healing properties, originally isolated from a protective protein in human gastric juice.
Noticed in days · Full benefit in weeks
Days 1-3
Pain relief typically begins as inflammation decreases at the injection site.
Week 1-2
Significant pain reduction and improved mobility are commonly reported.
Week 2-4
Tissue repair typically accelerates with visible improvement in function.
Week 4-8
Most injuries are typically substantially improved with continued healing.
BPC-157 is a peptide studied for its healing properties, originally isolated from a protective protein in human gastric juice. It's one of the most-researched compounds in this space, with over 100 published studies on tissue repair, gut healing, and inflammation, though the majority of that data comes from animal research. A human safety trial was published in 2025, and what we know about real-world results comes primarily from clinical practice.
How it works
When injected near an injury, BPC-157 concentrates locally rather than dispersing through the body. It works by triggering the growth of new blood vessels around damaged tissue, ramping up collagen production, and activating growth factors that accelerate the repair process. The reported effect is typically faster healing with improved tissue quality at the site.
Key benefits
What it’s been studied for:
- ✓Supports gastrointestinal repair and gut lining protection
- ✓Promotes new blood vessel growth around injured tissue
- ✓Accelerates healing across tendons, ligaments, muscles, and bones
- ✓Strengthens connective tissue through increased collagen production
- ✓Reduces local inflammation at the injury site
Regulatory status
Category 2. The FDA's pharmacy compounding advisory committee is scheduled to review BPC-157 on July 23, 2026, for potential addition to the 503A bulks list. The use under review: gut inflammation and inflammatory bowel conditions (ulcerative colitis). No formal rule change yet. Not FDA approved. Prohibited by WADA (added 2022) under S0, with no medical exemption available for athletes.
Journal · July 2026 PCAC
What the peptide panel is really voting on →
Injection
most studiedDirect tissue targeting for tendon, ligament, and muscle healing. The injection form delivers BPC-157 locally near the injury site for maximum repair effect. Half-life of 4 hours provides sustained local concentrations. This is the most studied route.
Injection protocols
| Protocol | Dose | Frequency |
|---|---|---|
| Tendon/joint healing | 250-500mcg | 1-2x daily |
| Serious injury | 500-1000mcg | 2x daily |
| General healing | 250-500mcg | 1-2x daily |
| Maintenance | 250mcg | 1x daily |
Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.
What people report
Pain relief typically begins as inflammation decreases at the injection site.
Significant pain reduction and improved mobility are commonly reported.
Tissue repair typically accelerates with visible improvement in function.
Most injuries are typically substantially improved with continued healing.
What to know
- ⚠Inject near the injury site on an empty stomach for the strongest local effect
- ⚠Mild redness or swelling at the injection site is common and temporary
- ⚠Use caution if you take blood thinners, as BPC-157 promotes blood vessel growth
- ⚠Avoid during pregnancy or breastfeeding
- ⚠Prohibited by WADA (World Anti-Doping Agency). Not cleared for competitive sports, and no medical exemption is available
- ⚠Talk to a healthcare provider before starting, especially if you have existing conditions
KEY RESEARCH · 5 PAPERS CITED
The Pep Dispatch
Follow the evidence on BPC-157 as it evolves.
Subscribe to find out what.
Next dispatch · May 2026 · Honest frequency: a few times a month
For the people who want to feel better — not just look up symptoms.